Inositol (I)
Key Takeaways Mounjaro (tirzepatide) mimics both GLP-1 and GIP receptors, differentiating it from GWegovy and Ozempic, which solely target GLP-1
Obesity Landscape - Final Thoughts Dosing The GLP-1 RA obesity market, driven by injectables, has seen historic levels of success, and near-term entrants are likely to provide more dosing options within the GLP-1 or GLP-1/GIP class Weight Loss Novel drugs in development are likely to be approved within the next 5 years, with improved weight loss efficacy compared to what Wegovy and Zepbound have demonstrated Body Comp The coming years will likely see increased data on muscle preservation and the quality of weight loss with novel MoAs, even if used in combination with GLP-1/incretin-targeting agents As the obesity market matures, how will patients think about the tradeoffs between efficacy, safety, and dosing/convenience with the availability of new drugs and more data

The state of Oregon and the city of Portland have been in a standoff with the Portland Trail Blazers over $600 million in proposed renovations needed at the stadium, while fears loom over whether or not the team will stick around in the Rose City
In a rat fracture model, IGF-1 combined with TGF- could stimulate chondrocyte proliferation and cartilage formation at the early stage of day 5 [8]
A healthy lifestyle WHO recommendations